Core Points - The article highlights the 10th anniversary of the collaboration between Chinese scientists and Cell Press, showcasing over 2400 original research papers published in various fields, indicating a significant growth in China's scientific contributions on the international stage [2] - The voting event for the "2024 Most Popular Chinese Papers" has commenced, encouraging readers to participate and support their favorite research papers [2][3] - The voting process is designed to foster resonance among researchers, allowing them to express appreciation for impactful discoveries or support esteemed scholars [2] Summary by Categories Life Sciences - The article mentions that the voting will cover five major fields, including life sciences, where impactful papers will be recognized [2][8] Material Sciences - The article lists several nominated papers in material sciences, emphasizing innovative research contributions from Chinese institutions [12] Medical Sciences - Notable medical research papers are highlighted, showcasing advancements in cancer treatment and public health studies [14] Cross-Disciplinary Sciences - The article includes nominations from cross-disciplinary research, reflecting the integration of various scientific fields [16] Sustainable Development - Papers related to sustainable development are also nominated, focusing on environmental health and carbon neutrality efforts in China [18]

Core Insights - The article discusses a groundbreaking clinical study published in the New England Journal of Medicine regarding the PRIMA system, a subretinal photovoltaic implant designed to restore vision in patients with geographic atrophy due to age-related macular degeneration (AMD) [2][3]. Group 1: Overview of AMD and PRIMA System - AMD is the most common type of irreversible blindness in the elderly, with dry AMD accounting for 85%-90% of cases, affecting over 5 million people globally [2]. - The PRIMA system, developed by Pixium Vision and acquired by Science Corporation, is a wireless, photovoltaic device implanted under the retina to replace lost photoreceptor cells [3][8]. Group 2: Clinical Study Details - The clinical study involved 38 patients aged 60 and above with advanced dry AMD, who underwent implantation of the PRIMA device and were assessed at 6 and 12 months post-surgery [6]. - After one year, 81% of patients experienced clinically significant improvement in central vision, allowing them to read letters and words, marking a shift from merely slowing disease progression to restoring perception [3][14]. Group 3: PRIMA System Components - The PRIMA system consists of three main components: 1. A subretinal photovoltaic chip measuring 2mm x 2mm and 30 micrometers thick, containing 378 pixel units [10]. 2. Specialized glasses that capture images and project signals to the implant [10]. 3. A portable processor for signal conversion and image adjustment [10]. Group 4: Safety and Efficacy - Among the 32 patients evaluated after 12 months, 26 (81%) showed clinically significant vision improvement, equivalent to seeing two additional lines on a standard vision chart [14]. - A total of 19 participants experienced 26 serious adverse events, with 81% occurring within two months post-surgery, and 95% of these events resolved within the same timeframe [17]. Group 5: Future Directions - The article notes that the PRIMA system is not the only approach being explored for AMD treatment, with ongoing research into stem cell therapy, optogenetics, and brain-machine interfaces to restore vision [17].

Core Viewpoint - Antibody-drug conjugates (ADCs) targeting TROP-2 show promise in treating advanced or metastatic solid tumors, demonstrating good anti-tumor activity and manageable safety profiles [2][4][8]. Group 1: TROP-2 and ADC Development - TROP-2 is a member of the epithelial cell adhesion molecule family, frequently overexpressed in various epithelial cancers while showing low or undetectable levels in normal tissues, making it a suitable target for ADCs [1]. - The development of several ADCs targeting TROP-2 has been prompted by its role in cancer cell proliferation, invasion, metastasis, and self-renewal, often associated with aggressive disease and poor prognosis [1]. Group 2: SHR-A1921 Clinical Study - The study published in Cancer Cell reports on the first-in-human phase 1 trial of SHR-A1921, an ADC developed by Heng Rui Medicine, targeting TROP-2 in patients with advanced or metastatic solid tumors [2][3]. - SHR-A1921 consists of a humanized TROP-2 IgG1 monoclonal antibody, a cleavable GGFG peptide linker, and a DNA topoisomerase I inhibitor, designed to enhance stability and minimize premature release of the cytotoxic payload [3]. Group 3: Safety and Efficacy Results - In the trial, 132 patients (33.8%) experienced grade ≥3 treatment-related adverse events, with oral mucositis being the most common, affecting 57 patients (14.6%) [4]. - The overall objective response rate was 24.8%, with response rates in specific cancer types ranging from 18.2% to 43.1%, indicating variable efficacy across different cohorts [4]. - No significant correlation was found between TROP-2 expression levels and treatment outcomes, suggesting that other factors may influence efficacy [4]. Group 4: Optimal Dosage and Future Directions - SHR-A1921 demonstrated the best efficacy and safety balance at a dose of 3.0 mg/kg administered every three weeks, making it a candidate for further clinical trials [7][8].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 能够采纳知识经验丰富的同类的视角，是一种高度适应性的能力。可能正因如此， 情感 传染 （情绪在个 体间传播的现象） 在 脊椎动物 中广泛存在。这种能力在 无脊椎动物 （尤其是社会性昆虫） 中可能同样 具有适应性价值，但昆虫微小的大脑是否具备这种协调能力，目前尚不明确。 2025 年 10 月 23 日， 南方医科大学 彭飞 教授团队在国际顶尖学术期刊 Science 上发表了题为： Positive affective contagion in bumble bees 的研究论文，该研究还被选为当期 封面论文 。 该研究证实， 熊蜂 中存在着积极情感传染，一只熊蜂的积极情绪状态会被另一只熊蜂迅速捕捉，从而影响 其行为决策。该研究还发现，熊蜂中的 情绪传染可通过 纯视觉信号传递 ，无需身体接触。 这项研究表明，情感传染的机制可能普遍存在于社会性脊椎动物以及社会性 昆虫中，暗示其进化根源可追 溯至更早期，并支持社会认知能力的趋同演化假说。 该封面图片展示了两只处于做了标记的处于 情感传染实验的管道中的熊蜂，在该管道中与处于积极情绪状态的同类短暂互 动过的熊蜂，后来对模棱两可 ...

Core Insights - The lithium-ion battery supply chain is crucial for global decarbonization, but its production is geographically dispersed, posing significant carbon management challenges [4][6] - A study published in Nature developed a Lithium Circular Computable General Equilibrium (LCCGE) model to assess decarbonization pathways, revealing a "value-emission paradox" in the supply chain [4][6] - The research emphasizes that global cooperation and localized strategies are key to achieving effective decarbonization [4][6] Supply Chain Carbon Footprint Dilemma - The lithium-ion battery market is projected to grow from $30 billion in 2020 to $180 billion by 2030, yet the carbon footprint from production can offset environmental benefits during usage [6] - The geographical distribution of the global supply chain complicates carbon accounting and reduction management [6] Value-Emission Paradox - Analysis from 2018-2022 shows that upstream mining contributes only 18.78% of economic value but accounts for 38.52% of carbon emissions, while downstream production generates 42.56% of value with only 34.82% of emissions [8] - This structural imbalance is particularly pronounced in resource-rich regions like the "Lithium Triangle" (Bolivia, Chile, Argentina) [8] Geographic Distribution and Carbon Inequality - China dominates production, accounting for 51.40% of global emissions, significantly higher than the "Lithium Triangle" [11] - The EU and the US are major net importers of embedded carbon, with the EU's consumption-based emissions being over six times its production-based export emissions in 2022 [11] Innovative Research Methodology - The LCCGE model integrates lifecycle thinking with global economic dynamics, allowing for comprehensive assessments of economic and environmental outcomes [13] - The study explores 1,036 integrated pathways for decarbonization, considering various socio-economic scenarios and recycling intensities [14] Complexity of Recycling Strategies - Recycling is essential for a circular economy, but its policy design requires careful consideration to avoid negative cross-regional spillover effects [16] - Consumer-oriented strategies yield the best global results, but their effectiveness varies across regions [16] Regional Differentiated Strategies - Optimal decarbonization is achieved through customized strategies rather than a one-size-fits-all global directive [18] - The study identifies that technology-trade cooperation is the most effective strategy for China, while developed economies benefit from environmental-technology collaboration [18] Efficiency vs. Equity Trade-off - Maximizing global efficiency may externalize environmental burdens to resource-exporting countries, highlighting the need for multi-objective approaches in policy design [20] - Strategies that appear globally optimal may not benefit all participants equally, necessitating robust frameworks to address distributional impacts [20] Feasible and Equitable Transition Framework - A comprehensive multi-level framework is essential for deep and equitable decarbonization of the lithium-ion battery supply chain [22] - The framework should be based on international cooperation and tailored approaches according to regional readiness, with a unified data platform for lifecycle carbon footprint standards [23]

Core Insights - The article discusses the launch of Genos, the world's first human genomic foundation model with 100 billion parameters, which aims to enhance the understanding of human genetics and its implications for clinical diagnosis and scientific research [2][4]. Group 1: Model Features and Capabilities - Genos supports ultra-long context analysis of up to one million base pairs and achieves single-base resolution for precise identification [3]. - The model integrates data from multiple authoritative resources, including the Human Pan-Genome Reference Consortium and the Human Genome Structural Variation Consortium, utilizing 636 high-quality human genomes to reduce data bias and represent human genetic diversity comprehensively [8]. - Genos employs a Mixture-of-Experts (MoE) architecture, allowing it to activate only the most relevant experts for specific tasks, thus optimizing resource consumption while maintaining a vast knowledge base [9]. Group 2: Performance Metrics - In various genomic tasks, Genos outperformed existing models in over half of the assessments, particularly excelling in long-sequence evaluation tasks such as mutation hotspot identification and population classification [11]. - The model achieved an accuracy of 92% in clinical applications for pathogenic mutation interpretation, which increased to 98.3% when combined with the 021 scientific foundation model [13][18]. Group 3: Accessibility and Applications - Genos is designed to be open-source, with both 1.2 billion and 100 billion parameter versions available for developers and researchers, facilitating easy deployment for downstream applications [21]. - The model is integrated into the DCS Cloud platform, allowing users to perform rapid RNA expression predictions based solely on DNA sequences, significantly speeding up biological data analysis [21]. - In clinical settings, Genos can provide expert-level multi-modal interpretations for genetic disease diagnosis and is also integrated into personal health platforms for personalized genomic reporting [22]. Group 4: Future Initiatives - The launch of Genos marks the beginning of a new era in genomic analysis, with ongoing initiatives like the Long100K Genomes Consortium and the 10BC project aimed at generating high-quality training data for future model iterations [23].

Core Insights - On October 22, 2025, a total of 22 papers were published in the prestigious journal Nature, with 11 authored by Chinese scholars, highlighting the significant contribution of Chinese researchers to global scientific advancements [3][6][9][12][14][16][19][20][22][23][25]. Group 1: Research Contributions - Ji Xinru from the Swiss Federal Institute of Technology published a paper on "Deterministic soliton microcombs in Cu-free photonic integrated circuits" [1]. - Li Feiya from Gladstone Institutes co-authored a paper titled "Myocardial reprogramming by HMGN1 underlies heart defects in trisomy 21" [2]. - A team from Beijing University of Technology, including Wu Yufeng and Yuan Haoran, published a paper on "A circular economy approach for the global lithium-ion battery supply chain" [3]. - Yan Hua from Florida Institute of Technology co-authored a paper on "Transcriptional interferences ensure one olfactory receptor per ant neuron" [4]. - Steven H. Lin from MD Anderson Cancer Center co-authored a paper titled "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" [5]. - Yan Yan from Harvard University published a paper on "Mapping Plasmodium transitions and interactions in the Anopheles female" [6]. - A team led by 崔屹 from Stanford University published a paper on "Cryogenic X-ray photoelectron spectroscopy for battery interfaces" [7]. - Liu Yulai from the University of Washington published a paper on "Bottom-up design of Ca2+ channels from defined selectivity filter geometry" [8]. - Yang Shubin from Beihang University co-authored a paper titled "Non-van der Waals superlattices of carbides and carbonitrides" [9]. - Cao Mingran from Francis Crick Institute published a paper on "Integration of hunger and hormonal state gates infant-directed aggression" [10]. - Xiong Kunli from Uppsala University co-authored a paper on "Video-rate tunable colour electronic paper with human resolution" [11].

Core Viewpoint - The research indicates that black phosphorus nanosheets (BPP) can enhance mitochondrial oxidative phosphorylation (OXPHOS) in tumor cells, potentially improving cancer immunotherapy outcomes [2][3][5][7]. Group 1: Research Findings - The study developed PEG-modified black phosphorus nanosheets (BPP) that metabolize into phosphates within tumor cells, promoting OXPHOS and improving cancer immunotherapy effectiveness [3][5]. - BPP regulates multiple signaling pathways, inhibits the expression of pro-survival genes, and reduces PD-L1 protein levels in melanoma cells, thereby suppressing cancer progression [5]. - BPP enhances immune regulation by increasing pro-inflammatory cytokine levels in serum, elevating CD8+ T cell levels in tumors and lymph nodes, and decreasing regulatory T cell (Treg) levels [5]. Group 2: Implications for Cancer Treatment - The research suggests that BPP may serve as a dual-function drug, combining tumor chemotherapy and immune enhancement capabilities [7].

Core Viewpoint - The article discusses the potential of SARS-CoV-2 mRNA vaccines as broad-spectrum immune activators that can sensitize tumors to immune checkpoint inhibitors (ICIs), significantly improving survival rates in advanced cancer patients [4][10]. Group 1: Impact of mRNA Vaccines on Cancer Treatment - Recent studies indicate that systemic administration of high-immunogenic mRNA nanoparticles can reset the immune microenvironment, making resistant tumors sensitive to ICIs [2]. - The research from MD Anderson Cancer Center shows that advanced cancer patients who received the SARS-CoV-2 mRNA vaccine within 100 days before starting ICI treatment had significantly extended overall survival [8]. - Specifically, the median survival for non-small cell lung cancer patients increased from 20.6 months to 37.3 months, and for metastatic melanoma patients, it rose from 26.7 months to over 36 months [8]. Group 2: Mechanism of Action - The study found that the SARS-CoV-2 mRNA vaccine significantly increased type I interferon (IFN-I) levels and activated antigen-presenting cells, which in turn stimulated CD8+ T cells to combat tumors [10][12]. - The vaccine also enhanced PD-L1 protein expression in tumors and promoted T lymphocyte activation within the tumor microenvironment [10]. Group 3: Clinical Implications - The findings suggest that clinically available mRNA vaccines targeting non-tumor-associated antigens can serve as powerful immune modulators, making tumors sensitive to ICIs [12]. - The combination of SARS-CoV-2 mRNA vaccines with ICIs can maintain T cell responses, thereby inhibiting tumor growth and improving cancer patient survival rates [12].

Core Insights - The study indicates that adipocyte lipolysis activates epithelial hair follicle stem cells through fatty acid metabolic signaling, promoting hair regeneration [4][11] - Local application of monounsaturated fatty acids can activate hair follicle stem cells to enhance hair growth [4][12] Group 1: Research Findings - The research published in Cell Metabolism reveals that skin injury triggers rapid lipolysis in adipocytes through inflammation, leading to hair regeneration [9][11] - Macrophages infiltrate the dermal adipose tissue post-skin injury, promoting the release of free fatty acids from adipocytes via serum amyloid A3 (SAA3) [8][12] - Epithelial hair follicle stem cells (eHFSC) absorb released monounsaturated fatty acids through the fatty acid transporter CD36, activating the transcriptional coactivator Pgc1-α, which enhances mitochondrial function and energy production [8][12] Group 2: Implications for Regeneration - The interaction between macrophages and adipocytes creates a signaling axis that facilitates tissue regeneration through short-range metabolic signaling via free fatty acids [11][12] - The findings suggest that similar regenerative mechanisms induced by fat inflammation may also play a role in other fat-rich organs [11]